Question 1

I had thyroid cancer, but not medullary. Am I excluded?

Accepted Answer

No, and the distinction is biological rather than a technicality. The warning names one tumor type: the calcitonin-producing C-cell cancer that makes up only about 1-2% of thyroid malignancy, plus the inherited syndrome that predisposes to it. The far more common types (papillary, follicular, Hürthle cell) grow from a different cell population entirely, and that population is not what the rodent findings concerned. A 2024 review in Thyroid traced the warning to rodent studies and found no conclusive evidence of raised thyroid cancer risk in people. In practice, survivors of the common subtypes who have finished treatment do receive these drugs routinely once oncology and endocrinology have signed off, and no label excludes them. Confirm what your pathology report said, and keep your surveillance schedule unchanged.

Question 2

I'm a breast cancer survivor on endocrine therapy. Is this safe?

Accepted Answer

Nothing in the labels excludes you, and the pooled evidence shows no consistent breast cancer signal for this class. Randomized trials pooled in 2021 turned up no statistically significant increase against comparators. A 2025 meta-analysis of randomized trials examining cancer outcomes across the class reached the same conclusion, breast cancer included. A large 2024 cohort in people with type 2 diabetes examined 13 obesity-associated cancers, post-menopausal breast among them, and found no elevated risk against insulin comparators. Endocrine therapy is not a listed interaction either. What matters more for you is practical rather than pharmacological: weight gain on endocrine therapy is common and is itself associated with worse outcomes, which is part of why this question comes up so often. Your oncologist should still be the one who signs it off, because timing relative to your treatment phase is a real consideration even when eligibility is not.

Question 3

Medullary thyroid cancer or MEN 2 runs in my family. Am I excluded?

Accepted Answer

Yes, absolutely, and this is the only cancer history in the labels that works this way. It applies whether or not you personally have been tested or diagnosed, and the reasoning has two parts. Rodent studies showed semaglutide, liraglutide and tirzepatide all producing thyroid C-cell tumors in proportion to dose and duration. And MEN 2 involves an inherited RET mutation that already predisposes that exact cell lineage toward malignancy, so the concern is overlap in the same cell type, not a vague theoretical worry. Every major trial in this class enforced the exclusion, from the liraglutide cardiovascular outcomes trial through the obesity and cardiovascular programs, which means no trial population exists that could tell you what happens if you take it anyway. If you find out after starting, the usual path is stopping, genetic counseling, considering RET testing, and asking about alternatives.

Question 4

Was the thyroid cancer only in rats?

Accepted Answer

The boxed warning rests entirely on rodent biology. The human outcomes data are a separate and inconsistent story. In rodents, all three drugs produced C-cell tumors scaling with dose and exposure time. Whether that carries over to humans is unknown. In humans, a 2023 French case-control study using national insurance data reported raised odds of thyroid cancer of all subtypes at one to three years of exposure. But a considerably larger Scandinavian cohort across three national registries, comparing against another actively managed drug class, found no overall increase. A 2024 review in Thyroid found no conclusive evidence of raised risk in people and flagged surveillance bias as a problem the observational studies had not dealt with: people on these drugs are examined more often, and examination finds things. None of this retires the contraindication above, because that rests on different evidence and a different question.

Question 5

Is the old pancreatic cancer worry still live?

Accepted Answer

Largely walked back, and by better methods than produced it. The concern traces to early observational reports in the early 2010s involving two much older drugs, and the evidence since has not supported it. A 2023 Mendelian randomization analysis found no consistent link between the GLP-1 receptor and breast, colorectal, prostate or overall cancer, though it did not examine pancreatic cancer itself. That method uses genetic variants as stand-ins for lifetime receptor activation, which makes it far more resistant to confounding than an observational cohort. A 2024 cohort of 1.6 million people with type 2 diabetes found pancreatic cancer risk lower on GLP-1 drugs than on insulin (hazard ratio 0.41), and reduced risk for 10 of 13 obesity-associated cancers. Nor did a 2025 meta-analysis of randomized trials find a significant pancreatic signal. What has not been walked back is pancreatitis, which remains a documented if uncommon labeled adverse event. It is a different condition from cancer, with its own warning signs.

Question 6

I'm a colorectal cancer survivor. Can I take one?

Accepted Answer

Nothing in any label excludes you, and most of the human evidence shows no colorectal signal. The 1.6-million-patient cohort examined colorectal cancer among 13 obesity-associated sites and found its risk lower on GLP-1 drugs than on insulin (hazard ratio 0.54), though not significantly different from metformin. The Mendelian randomization analysis found no causal increase. The 2025 randomized-trial meta-analysis is the exception. It found a small rise in colorectal cancer diagnoses (odds ratio 1.27), significant only in shorter trials, which its authors suggest may reflect extra diagnostic testing prompted by the drugs' gut side effects. Two lines of evidence with different weaknesses point to no harm, and the third has a plausible detection explanation. The practical considerations for you are about surveillance rather than eligibility: keep to your scheduled colonoscopies, and read the scope answer below, because holding doses before a procedure matters more for someone on a surveillance schedule than for the general population. Discuss timing with oncology if abdominal symptoms are part of your history.

Question 7

Do these drugs actually lower any cancer risk?

Accepted Answer

The data lean that way, and the mechanism is almost certainly the weight rather than the drug. That distinction changes what you should expect. The 1.6-million cohort found statistically reduced incidence across several of the 13 obesity-associated cancers against insulin comparators, among them gallbladder and liver, ovarian, pancreatic, colorectal and meningioma. Long-term SELECT follow-up documented sustained weight loss around 10% at four years, and weight loss of that size has long been linked in epidemiology to fewer obesity-attributable cancers. Be careful with site-by-site findings, though: analyses that slice a cohort into 13 sites will produce some positive results by chance, so the reduction is suggestive rather than established. The randomized-trial meta-analysis found no overall increase, which is the more solid claim and the one to rely on.

Question 8

I already have thyroid nodules. Is that a problem?

Accepted Answer

Almost certainly not. Nodules turn up in something like one adult in two once anyone scans carefully, and having one is not a contraindication on any label in this class. The exclusion names medullary thyroid carcinoma and MEN 2 specifically. Most nodules are benign, and the standard approach is unchanged by the drug: characterize by ultrasound features and biopsy selectively where size and risk warrant it. The 2024 Thyroid review found no conclusive evidence of raised thyroid cancer risk and found no evidence supporting nodule screening before or during treatment, and the Scandinavian registry cohort found no overall thyroid cancer signal against a comparator class. What to do is administrative rather than medical. Disclose the nodules, hand over the most recent ultrasound and TSH, and let endocrinology set the surveillance interval rather than changing it because you started a new drug.

Question 9

Do I hold doses before a colonoscopy or endoscopy?

Accepted Answer

In most current practice yes, and for survivors on surveillance it matters more than for anyone else. A 2024 study that scanned stomachs by ultrasound before anesthesia found increased residual contents in 56% of people taking these drugs against 19% of those who were not, about two and a half times the prevalence after adjustment. For someone on a regular scope schedule that cuts two ways. Retained contents raise aspiration risk under sedation, and they can also obscure the view, which for a surveillance colonoscopy or staging endoscopy means a compromised examination, not merely a delayed one. Society guidance varies, but the common pattern is skipping the weekly dose five to seven days beforehand with an extended clear-liquid fast the day before. Whoever is sedating you and whoever is holding the scope decide together, once they know how long you have fasted and what the procedure involves. Disclose it at pre-procedure intake without waiting to be asked.

Question 10

Will my oncologist agree during or just after treatment?

Accepted Answer

It depends on your cancer, your treatment phase and their judgment. There is no blanket oncology contraindication beyond the medullary thyroid and MEN 2 exclusion. But one situation is close to a clear no: active treatment involving unintentional weight loss. Adding an appetite suppressant to someone already losing weight they cannot afford to lose is the wrong drug at the wrong time, whatever the cancer. Beyond that, chemotherapy, immunotherapy and radiation bring their own nausea, vomiting, anorexia and fatigue, all of which overlap with GLP-1 titration. Many oncologists prefer to wait until you are past acute treatment and stable, because you cannot tell the two apart while both are running. In remission the calculation shifts toward weight regain and managing obesity-related conditions. No study here measured recurrence directly, but the wider cancer evidence shows no across-the-board signal. The 13-site cohort, which tracked first-time cancers, found several sites lower against insulin, though kidney cancer was higher against metformin, and the pooled randomized trials found no significant increase in cancer overall.

GLP-1s With a Cancer History: 10 Questions, Answered by Site

Q1.I had thyroid cancer, but not medullary. Am I excluded?

Q2.I'm a breast cancer survivor on endocrine therapy. Is this safe?

Q3.Medullary thyroid cancer or MEN 2 runs in my family. Am I excluded?

Q4.Was the thyroid cancer only in rats?

Q5.Is the old pancreatic cancer worry still live?

Q6.I'm a colorectal cancer survivor. Can I take one?

Q7.Do these drugs actually lower any cancer risk?

Q8.I already have thyroid nodules. Is that a problem?

Q9.Do I hold doses before a colonoscopy or endoscopy?

Q10.Will my oncologist agree during or just after treatment?

References

Questions and answers